CX Institutional
VRTX icon

CX Institutional’s Vertex Pharmaceuticals VRTX Stock Holding History

CX Institutional’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$987K Buy
1,888
+50
+3% +$25.6K 0.03% 332
2026
Q2 		$913K Sell
1,838
-102
-5% -$45.2K 0.03% 346
2026
Q1 		$866K Buy
1,940
+2
+0.1% +$933 0.03% 362
2025
Q4 		$879K Buy
1,938
+132
+7% +$56.9K 0.03% 308
2025
Q3 		$707K Buy
1,806
+52
+3% +$21.7K 0.02% 352
2025
Q2 		$781K Sell
1,754
-33
-2% -$15.2K 0.03% 306
2025
Q1 		$866K Buy
1,787
+148
+9% +$69K 0.03% 291
2024
Q4 		$660K Buy
1,639
+11
+0.7% +$5.1K 0.03% 306
2024
Q3 		$757K Buy
1,628
+3
+0.2% +$1.44K 0.03% 318
2024
Q2 		$762K Sell
1,625
-18
-1% -$7.81K 0.04% 318
2024
Q1 		$687K Sell
1,643
-37
-2% -$15.6K 0.03% 328
2023
Q4 		$684K Sell
1,680
-21
-1% -$7.76K 0.04% 299
2023
Q3 		$592K Sell
1,701
-23
-1% -$8.04K 0.03% 313
2023
Q2 		$607K Buy
1,724
+3
+0.2% +$1.01K 0.03% 330
2023
Q1 		$544K Buy
1,721
+425
+33% +$127K 0.03% 342
2022
Q4 		$374K Buy
1,296
+95
+8% +$29K 0.02% 403
2022
Q3 		$348K Buy
1,201
+480
+67% +$138K 0.02% 376
2022
Q2 		$204K Buy
+721
New +$193K 0.02% 436
2021
Q4 		– Sell
-47
Closed -$9K – 883
2021
Q3 		$9K Sell
47
-287
-86% -$56K ﹤0.01% 845
2021
Q2 		$67K Sell
334
-64
-16% -$13.4K 0.01% 512
2021
Q1 		$86K Buy
398
+86
+28% +$18.9K 0.01% 401
2020
Q4 		$74K Buy
312
+154
+97% +$35.3K 0.01% 395
2020
Q3 		$43K Buy
158
+28
+22% +$7.72K ﹤0.01% 411
2020
Q2 		$38K Buy
130
+22
+20% +$5.96K 0.01% 362
2020
Q1 		$26K Buy
108
+55
+104% +$12.6K ﹤0.01% 353
2019
Q4 		$12K Buy
53
+4
+8% +$810 ﹤0.01% 416
2019
Q3 		$8K Buy
+49
New +$8.67K ﹤0.01% 505
2019
Q2 		– Sell
-25
Closed -$5K – 996
2019
Q1 		$5K Buy
+25
New +$4.62K ﹤0.01% 558

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

CX Institutional's VRTX Position: Q3 2026 in Review

CX Institutional increased its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q3 2026, buying an estimated $25.6K and bringing the position to 1,888 shares worth $987K. The position accounts for 0.03% of the portfolio, ranked #332.

CX Institutional first reported a position in VRTX in Q1 2019 and has held it in 28 quarters since. 386 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • CX Institutional held 1,888 shares of Vertex Pharmaceuticals worth $987K as of Q3 2026.
  • CX Institutional bought 50 Vertex Pharmaceuticals shares in Q3 2026, an estimated $25.6K.
  • Vertex Pharmaceuticals made up 0.03% of CX Institutional's portfolio in Q3 2026, its #332 holding.
  • CX Institutional first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • 386 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.